Top hypotheses to guide molecular targeted therapies and lifestyle biomarker panels for PCa in ABCD relate to such MCP‐1, IL‐1β, and CXCL1 signaling, as well as gut microbiome dysbiosis and exposure of the periprostatic white adipose tissue to the prostate microbiome. This evidence concerns the gene CXCL1 and posterior cortical atrophy.